HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP)

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Acurx Pharmaceuticals has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Down 3.0%

ACXP traded down $0.04 during midday trading on Tuesday, hitting $1.30. The company had a trading volume of 156,983 shares, compared to its average volume of 1,112,318. Acurx Pharmaceuticals has a 52 week low of $1.27 and a 52 week high of $8.34. The company has a market capitalization of $7.23 million, a price-to-earnings ratio of -0.48 and a beta of -2.02. The stock’s 50 day moving average price is $1.43 and its 200 day moving average price is $2.08.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.15). Research analysts predict that Acurx Pharmaceuticals will post -2 EPS for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.